SLP - Simulations Plus, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
19.60
+0.36 (+1.87%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.24
Open19.27
Bid18.00 x 900
Ask19.86 x 3100
Day's Range19.27 - 19.99
52 Week Range14.25 - 23.95
Volume69,633
Avg. Volume63,566
Market Cap342.212M
Beta (3Y Monthly)0.02
PE Ratio (TTM)40.00
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (1.24%)
Ex-Dividend Date2019-01-24
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 days ago

    DILIsym Awarded $1.5 Million Phase II NIH Grant

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.

  • Business Wire4 days ago

    Simulations Plus Releases DDDPlus™ Version 6

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.

  • Business Wire5 days ago

    DILIsym Services Inc. Initiates Development of IPFsym™

    DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF). The development of IPFsym is being sponsored by a large pharmaceutical company partner for $2.7 million, and it will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.

  • Business Wire9 days ago

    Simulations Plus to Present at the 21st Annual Needham Growth Conference

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will present at the 21st Annual Needham Growth Conference in New York City on Wednesday, January 16, 2019, at 8:40 a.m. ET (5:40 a.m. PT). In addition to his presentation, Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.

  • Business Wire10 days ago

    Simulations Plus Reports First Quarter FY2019 Financial Results

    First quarter net revenues of $7.5 million reflecting 6.6% year over year growth

  • Business Wire12 days ago

    DILIsym Services Inc. Releases DILIsym® Version 8A

    DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it has released DILIsym® Version 8A, its flagship QST (quantitative systems toxicology) modeling software. Dr. Paul Watkins, chair of the DILI-sim Scientific Advisory Board, said: “The DILI-sim Initiative input has led to this release of an updated version of the DILIsym tool. DILIsym version 8A includes many new important example compounds and addresses, for the first time, drug-induced injury to bile duct cells.

  • Business Wire17 days ago

    Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results

    Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST

  • Business Wire2 months ago

    Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018

    Simulations Plus, Inc. (SLP), a leading provider of software for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD Micro Main Event investor conference at 9 a.m. PT on Tuesday, December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los Angeles, California. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

  • Business Wire2 months ago

    Simulations Plus Reports FY2018 and Fourth Quarter FY2018 Financial Results

    Full Fiscal Year Pharmaceutical Software and Services Revenues Up 22.9%; Earnings per share of $0.50, up 51.4% over prior year

  • Business Wire2 months ago

    Simulations Plus to Report 4th Quarter and Fiscal Year 2018 Financial Results

    Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET

  • Business Wire2 months ago

    DILIsym Services, an SLP Company, Launches Consortium for Drug-Related Kidney Injury

    DILIsym Services, Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety, today announced that it will initiate a quantitative systems toxicology (QST) consortium aimed at addressing the problem of drug-induced kidney injury, the third leading cause for clinical and late stage drug attrition in pharmaceutical development.

  • Business Wire3 months ago

    Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock. The cash dividend will be distributed on Thursday, November 8, 2018, to shareholders of record as of Thursday, November 1, 2018. Walt Woltosz, chairman of the board of directors, said, “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.06 per share per quarter.

  • Business Wire4 months ago

    Simulations Plus Receives New Grant Award from the FDA

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that it has been awarded a new funded cooperative agreement, for $250,000 per year for up to two years, to integrate drug product quality attributes into the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™.

  • Business Wire4 months ago

    Simulations Plus Extends Funded Research Collaboration with the FDA

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded extension to its previous cooperative agreement (grant 1U01FD005211) with the U.S. Food and Drug Administration (FDA) to further develop and validate the mechanistic Ocular Compartmental Absorption and Transit (OCAT™) model in GastroPlus™.

  • ACCESSWIRE6 months ago

    Ex-Dividend Schedule: Simulations Plus Has a Dividend Yield of 1.32%; Will Trade Ex-Dividend on July 25, 2018

    LONDON, UK / ACCESSWIRE / July 24, 2018 / Active-Investors has a free review on Simulations Plus, Inc. (NASDAQ: SLP) following the Company's announcement that it will begin trading ex-dividend on July 25, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 24, 2018. Active-Investors has initiated due-diligence on this dividend stock.

  • Business Wire6 months ago

    Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development

    DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The grant, coauthored by Dr. Brett Howell (Principal Investigator) and Dr. Bud Nelson, is entitled “Software for predicting a drug’s potential to cause acute kidney injury.” The total award for this Fast Track SBIR grant is up to $1.7 million over the next 18-24 months.

  • Business Wire6 months ago

    Simulations Plus Enters Funded Research Collaboration with Large European Consortium

    Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a one-year funded research collaboration with a large European consortium to further develop and validate the mechanistic Transdermal Compartmental Absorption and Transit (TCAT™) model in GastroPlus™. Dr. Viera Lukacova, director of simulation sciences, said: “We are very pleased to have the opportunity to work with the diverse membership of this large European consortium to enhance the GastroPlus TCAT model in support of alternative approaches to animal testing. The model is already being utilized heavily within pharmaceutical companies to support transdermal product development activities.

  • Business Wire6 months ago

    Simulations Plus Reports Third Quarter FY2018 Financial Results

    Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%

  • ACCESSWIRE6 months ago

    Simulations Plus, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Simulations Plus, Inc. (NASDAQ: SLP ) will be discussing their earnings results in their Q3 Earnings Call to be held on July 10, 2018 at 4:15 PM Eastern Time. ...

  • Business Wire7 months ago

    Company Profile for Simulations Plus, Inc.

    Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology/toxicology models for drug-induced liver injury and nonalcoholic fatty liver disease.

  • Business Wire7 months ago

    Simulations Plus to Report Third Quarter 2018 Financial Results

    Simulations Plus, Inc. (SLP), announced today that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018. The Company invites all interested persons to attend its conference call at 4:15 p.m. Eastern Time on July 10, 2018. Simulations Plus, Inc., is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions.

  • Business Wire7 months ago

    Simulations Plus Releases ADMET Predictor™ Version 9

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has released version 9 of its flagship artificial intelligence modeling program, ADMET Predictor™.

  • Business Wire7 months ago

    Simulations Plus Names Shawn O’Connor as CEO

    Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that Shawn M. O’Connor will become its chief executive officer effective June 26, 2018. Mr. O’Connor brings more than three decades of executive experience from multiple industries with companies ranging from start-ups to publicly traded companies and a proven track record for strategy definition, building strong organizations, optimizing revenue, profitability, and cash flow, and creating value for investors.

  • Business Wire8 months ago

    Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018

    Simulations Plus, Inc. , the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemical industries, today announced that it will participate in the 8th Annual LD Micro Invitational Investor Conference to be held at the Luxe Sunset Boulevard Hotel in Los Angeles.